Tag Archive for: 2seventy bio

Cancer treatment maker 2seventy bio,  said it will sell all its experimental cell therapies to Regeneron Pharmaceuticals to focus on its only approved product Abecma.

The company will save about $130 million in 2024-25 as it eliminates 176 roles.

Following the death of a patient, the FDA has placed a clinical hold on Arcellx’s iMMagine-1 Phase II trial of its T cell therapy for relapsed or refractory multiple myeloma. The company’s stock fell around 23% in pre-market trading Tuesday.  

Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal trial of their B-cell maturation antigen–directed (BCMA) CAR T-cell therapy in multiple myeloma patients who had received two to four prior lines of therapy.